Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8715689 | Journal of Dermatological Science | 2018 | 9 Pages |
Abstract
RvD1 can obviously improve skin inflammation in IMQ-induced mice psoriasiform dermatitis. The protective mechanisms might be related to its selective reaction with lipoxin A4 receptor/Formyl-peptide receptor 2 (ALX/FPR2), by downregulating relevant cytokines of the IL-23/IL-17 axis expression, the inhibition of MAPKs and NF-κB signaling transduction pathways. Thus, these results show that RvD1 could be a possible candidate for psoriasis therapy.
Keywords
NF-κB p65RvD1nuclear factor kappa B p65IMQIL-23BOCIL-17IL-22qRT-PCRGAPDHMAPKsResolvin D1inflammationImiquimodInterleukin-22Interleukin-23interleukin-17PASItumor necrosis factor alphaTNF-αpsoriasis area and severity indexquantitative real-time PCRPsoriasisKeratinocytemitogen-activated protein kinasesglyceraldehyde-3-phosphate dehydrogenase
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Juntao Xu, Xiaoru Duan, Feng Hu, Devesh Poorun, Xinxin Liu, Xin Wang, Song Zhang, Lu Gan, Mengwen He, Ke Zhu, Zhangyin Ming, Hongxiang Chen,